Juergen Froehlich
Hoofd Techniek/Wetenschap/O&O bij ARCTURUS THERAPEUTICS HOLDINGS INC.
Vermogen: - $ op 31-05-2024
Profiel
Juergen Kurt Froehlich is currently an Independent Director at Appili Therapeutics, Inc., a Chief Medical & Development Officer at Spexis Ltd., and a Chief Medical Officer at Arcturus Therapeutics Holdings, Inc. Previously, he held positions as the Chief Medical Officer at Aradigm Corp.
from 2018 to 2019 and from 2013 to 2018, as well as the Chief Marketing Officer at EnBiotix, Inc. from 2022 to 2023 and the Head-Regulatory Affairs at Vertex Pharmaceuticals, Inc. from 2011 to 2013.
He has an MBA from the State University of New York at Albany and the Graduate School of Business Administration Zürich, as well as a doctorate from Julius-Maximilians-Universität Würzburg.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 29-04-2024 | 0 ( -.--% ) | - $ | 31-05-2024 |
Actieve functies van Juergen Froehlich
| Bedrijven | Functie | Begin |
|---|---|---|
| APPILI THERAPEUTICS INC. | Directeur/Bestuurslid | 27-01-2020 |
| SPEXIS AG | Hoofd Techniek/Wetenschap/O&O | 30-12-2021 |
| ARCTURUS THERAPEUTICS HOLDINGS INC. | Hoofd Techniek/Wetenschap/O&O | - |
Eerdere bekende functies van Juergen Froehlich
| Bedrijven | Functie | Einde |
|---|---|---|
EnBiotix, Inc.
 EnBiotix, Inc. Medical/Nursing ServicesHealth Services EnBiotix, Inc. operates as a late clinical-stage respiratory therapeutics company, which engages in deploying novel systems and synthetic biology technologies. It offers anti-persisters, engineered bacteriophage, tunable target degradation, and systems biology platform. Its pipeline includes ColiFin, EBX-001, EBX-002, and Linear Peptide Antibiotics. The company was founded by James J. Collins in 2012 and is headquartered in Boston, MA. | Verkoop & Marketing | 01-04-2023 |
| ARADIGM CORPORATION | Hoofd Techniek/Wetenschap/O&O | 14-02-2019 |
| ARADIGM CORPORATION | Hoofd Techniek/Wetenschap/O&O | 11-02-2018 |
| VERTEX PHARMACEUTICALS INCORPORATED | Algemeen Adviseur | 01-09-2013 |
Opleiding van Juergen Froehlich
| Julius-Maximilians-Universität Würzburg | Doctorate Degree |
| State University of New York at Albany | Masters Business Admin |
| Graduate School of Business Administration Zürich | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 4 |
|---|---|
| APPILI THERAPEUTICS INC. | Health Technology |
| SPEXIS AG | Health Technology |
| ARCTURUS THERAPEUTICS HOLDINGS INC. | Health Technology |
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Aradigm Corp.
 Aradigm Corp. Pharmaceuticals: MajorHealth Technology Aradigm Corp. was a pharmaceutical company, which was focused on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases by pulmonologists. The company was founded in 1991 and was headquartered in Hayward, CA. | Health Technology |
EnBiotix, Inc.
EnBiotix, Inc. Medical/Nursing ServicesHealth Services EnBiotix, Inc. operates as a late clinical-stage respiratory therapeutics company, which engages in deploying novel systems and synthetic biology technologies. It offers anti-persisters, engineered bacteriophage, tunable target degradation, and systems biology platform. Its pipeline includes ColiFin, EBX-001, EBX-002, and Linear Peptide Antibiotics. The company was founded by James J. Collins in 2012 and is headquartered in Boston, MA. | Health Services |
